On the first trading day of this week, the main indexes of the market opened low, with the trade and retail, power equipment, and national defense and military sectors leading the decline, and the concepts of shipping, blood products, traditional Chinese medicine, and innovative drugs strengthened against the market, and the constituent stocks of the Science and Technology Innovation 100 Index performed differentiated, pharmaceutical stocks rose in the front, Shenzhou Cell rose more than 5%, and the Science and Technology Innovation 100 ETF China AMC (588800), which tracks the index, was actively traded and the premium was obvious.
According to the data, the Science and Technology Innovation 100 ETF China AMC (588800) closely tracks the SSE Science and Technology Innovation Board 100 Index, and selects 100 ** with medium market value and good liquidity from the Science and Technology Innovation Board in addition to the Science and Technology Innovation 50 as samples, which is the first and only small and medium-cap style index on the Science and Technology Innovation Board, focusing on high-growth science and technology innovation dark horses, and the growth style is more extreme.
Last week, the annual important economic meeting was held to deploy the direction of work for the next year, and under the high-quality development, some structural highlights are expected to appear in the follow-up policies, and some science and technology industry policies may exceed expectations. Huaan** believes that in this round of liquidity-driven, the Kechuang 100 is expected to benefit from higher valuation elasticity.
Recently, funds have taken advantage of the Science and Technology Innovation 100 ETF ChinaAMC (588800) to lay out the small and medium-sized stocks of the Science and Technology Innovation Board on a dip, and in just over 20 trading days after listing, the Science and Technology Innovation 100 ETF ChinaAMC (588800) has strongly "attracted gold" 33400 million yuan, well recognized by the market.
The content and data are for reference only and do not constitute investment advice. AI technology strategy is provided for Youlian Cloud.